Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Obatoclax in older patients with previously untreated AML
NCT00684918Phase 2Completed
- Sponsor
- Gemin X Pharmaceuticals
- Start
- Apr 2008
- Primary completion
- Aug 2009
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, open-label trial of obatoclax in acute myeloid leukemia (AML) (2 arms), sponsored by Gemin X Pharmaceuticals. Primary endpoint: Rate of Morphologic Complete Remission at 4 weeks. Started Apr 2008; status: completed.
02
Drugs
obatoclax
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT00684918.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00684918.